1-6 of 6
Thomas W. Dubensky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors

Available to Purchase
Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien, Debebe Theodros, Kelsey E. Sivick, Gabrielle L. Reiner, Laura Hix Glickman, Ariel E. Marciscano, Andrew B. Sharabi, Meredith L. Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr, Drew M. Pardoll, Charles G. Drake
Journal: Cancer Immunology Research
Cancer Immunol Res (2018) 6 (4): 422–433.
https://doi.org/10.1158/2326-6066.CIR-17-0263
Published: 01 April 2018
View articletitled, TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
Open the PDF for TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors in another window
Includes: Supplementary data
Journal Articles

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

Available to Purchase
Jeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, Bridget C. Marcinkowski, Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky, Jr, Leisha A. Emens
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (6): 468–479.
https://doi.org/10.1158/2326-6066.CIR-16-0284
Published: 01 June 2017
View articletitled, A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Open the PDF for A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice in another window
Includes: Supplementary data
Journal Articles

Abstract B50: Synergistic antitumor efficacy in mice with immunotherapy regimens combining recombinant live-attenuated Listeria with immune checkpoint inhibitors

Free
Weiwen Deng, Weiqun Liu, Thomas Hudson, Chris S. Rae, Ed Lemmens, Anthony Desbien, Bill Hanson, Pete Lauer, Thomas W. Dubensky, Jr., Meredith Leong
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (3_Supplement): B50.
https://doi.org/10.1158/2326-6074.TUMIMM16-B50
Published: 28 February 2017
View articletitled, Abstract B50: Synergistic antitumor efficacy in mice with immunotherapy regimens combining recombinant live-attenuated Listeria with immune checkpoint inhibitors
Journal Articles

Abstract B020: STING activation in the tumor microenvironment using a synthetic human STING-activating cyclic dinucleotide induces potent antitumor immunity

Free
Sarah M. McWhirter, Laura Hix Glickman, Tony Desbien, Kelsey Sivick Gauthier, David Kanne, Shailaja Kasibhatla, Jie Li, AnneMarie Culazzo Pferdekamper, George Katibah, Ed Lemmens, Leticia Corrales, Meredith Leong, Chudi Ndubaku, Justin Leong, Leonard Sung, Lianxing Zheng, Charles Cho, Yan Feng, Jeffery M. McKenna, John A. Tallarico, Steven L. Bender, Thomas W. Dubensky, Jr.
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (11_Supplement): B020.
https://doi.org/10.1158/2326-6066.IMM2016-B020
Published: 31 October 2016
View articletitled, Abstract B020: STING activation in the tumor microenvironment using a synthetic human STING-activating cyclic dinucleotide induces potent antitumor immunity
Journal Articles

Abstract A013: Favorable changes in tumor microenvironment following intravenous dosing with live attenuated Listeria monocytogenes-based immunotherapy

Free
Weiwen Deng, Takahiro Tsujikawa, Nitya Nair, Thomas Hudson, Weiqun Liu, Chris S. Rae, Edward E. Lemmens, Anthony W. Desbien, William Hanson, Peter Lauer, Lisa M. Coussens, Dirk G. Brockstedt, Thomas W. Dubensky, Jr., Meredith L. Leong
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (11_Supplement): A013.
https://doi.org/10.1158/2326-6066.IMM2016-A013
Published: 31 October 2016
View articletitled, Abstract A013: Favorable changes in tumor microenvironment following intravenous dosing with live attenuated Listeria monocytogenes-based immunotherapy
Journal Articles

Abstract IA10: Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives

Free
Laura Hix Glickman, Leticia Corrales, Sarah M. McWhirter, David B. Kanne, Kelsey E. Sivick, Jason R. Baird, Edward Lemmens, Justin J. Leong, Ken Metchette, Mark Crittenden, Michael Gough, Thomas F. Gajewski, Thomas W. Dubensky, Jr
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): IA10.
https://doi.org/10.1158/2326-6074.TUMIMM14-IA10
Published: 09 October 2015
View articletitled, Abstract IA10: Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives